This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The FDA has given compounding pharmacies and facilities a deadline of April 22, 2025 or May 22, 2025 (depending on the type of compounding pharmacy or facility) to stop offering compounded semaglutide. It remains to be seen how long compounded semaglutide products will be available.
Source: ADA, 2025 Type 2 diabetes Type 2 diabetes accounts for about 94% of diabetes cases in adults in the U.S. ADA, 2025) Men are slightly more likely than women to be diagnosed with Type 2 diabetes. ADA, 2025) Men are slightly more likely than women to be diagnosed with Type 2 diabetes. of Lantus users and 23.1%
Authored By: Aneeka Chavda, MRPharmS, MSc, MCMI, PgDipClinPharm Posted 19 June 2025 Mycobacterium tuberculosis (TB ) is one of the leading causes of death globally. Finally, the use of fluoroquinolones are discussed, especially for drug-resistant or intolerant patients, noting their potential in CNS TB and as part of shorter-course therapies.
Common adversereactions in pediatric patients included viral infections, nasopharyngitis, and cough, but the drug was generally well-tolerated. In pediatric patients with persistent or chronic ITP, the most common adversereactions (10% or more) included viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain.
While the European Medicines Agency mandated pre-treatment DPD testing in Europe as early as 2020, and the UK’s National Health Service followed suit the same year, the US only reached a consensus in 2025. Accessed July 21, 2025. Accessed July 21, 2025. Accessed July 21, 2025. European Medicines Agency. link] NHS England.
Additionally, the safety profile of clesrovimab-cfor was seen to be comparable to placebo, with most adversereactions being mild to moderate. The most common adversereactions were injection-site erythema, injection-site swelling and rash. June 9, 2025. Accessed June 10, 2025. News Release.
Common adversereactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. The CRL was received after OLC’s initial Prescription Drug User Fee Act date of June 28, 2025, and cited for deficiencies that are unrelated to OLC itself. June 30, 2025. News release.
Most adversereactions were mild, with injection site pain the most common local effect. Fatigue, headache and myalgia were the most reported systemic reactions. There were no notable differences between groups in terms of unsolicited or serious adverse events. Safety results were consistent with earlier phase 3 data.
3 The safety profile was favorable with the most common adverse effect (AE) being increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.
While no new adversereactions were observed in this study, higher rates of hypersensitivity and infusion-related reactions were observed. July 9, 2025. Accessed July 9, 2025. Accessed July 9, 2025. Accessed July 9, 2025. Eli Lilly and Company. News release. Mayo Clinic. Alzheimer’s Disease.
Lets take a look at these letters: Back in January 2025, CVM issued a Warning Letter to animal drug sponsor Elanco Animal Health. Further, information presented on the adversereaction data was inconsistent with the PI. The detail with which CVM reviewed these promotions is reminiscent of OPDP/DDMAC letters of yore.
An adversereaction to mold can be a trigger for Hashimotos, asthma, and other autoimmune conditions. [23] Accessed February 20, 2025. Published online January 6, 2025. Accessed February 20, 2025. Accessed February 27, 2025. Some molds produce toxic secondary metabolites called mycotoxins. 3] Faber S.
July 7, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Pivya has been proven safe in three studies. Alembic plans to make Pivya available in the US in the fourth quarter of 2025.” The most common adversereactions are diarrhoea, nausea, vulvovaginal candidiasis, genital pruritus and headache.
1,2 The most common adversereactions are abdominal pain, diarrhea, dizziness, flatulence, headache, nausea, soft feces, vomiting, and vulvovaginal candidiasis. Accessed April 1, 2025. March 25, 2025. Accessed April 1, 2025. It has not been studied in patients younger than 12 years or who weigh less than 40 kg.
‘Almost a third of adversereactions to medicines could be prevented with the introduction of genetic testing… This has the potential to transform our safety monitoring activities – enabling us to meet a real need by using high-quality patient data to reduce side effects of medicines.’
Adversereactions in adults included dermatitis acneiform, diarrhoea, nausea and musculoskeletal pain. In children, reactions included elevated blood creatine phosphokinase, abdominal pain, vomiting and headache. EZMEKLY is available in tablet form that dissolves in water, helping those unable to swallow pills.
Patients ages 75 and older with renal impairment may have diminished glycemic efficacy when taking Jardiance, causing an incidence of volume depletion-related adversereactions and urinary tract infections. Although there is no generic version of Jardiance available currently, there may be as early as 2025.
pharmacy shelves in July 2025. One study reported , Prices for biosimilars are typically 15% to 35% lower than their respective brand-name reference biologic and can prompt the brand-name manufacturers to lower prices or offer discounts. What are the side effects of Merilog? When will Merilog be available? Merilog is expected to hit U.S.
People Who Are Sensitive/Reactive to Thyroid Medications: People who are sensitive to thyroid medications, or the fillers contained in many of them, or who have had adversereactions to their medications, may benefit from using natural treatments as an alternate way to lower TSH levels and support their symptoms. SpringerOpen.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content